Startups channel feed – Endpoints News

Startups channel feed

Updated: Flagship merges its troubled circular RNA company Laronde with nanoparticle startup Senda

Last year

Scoop: Eli Lilly agrees to acquire another European ADC biotech

Last year

Ultragenyx to spin off company to develop ‘high risk, high return’ gene therapy for Alzheimer’s disease

Last year

Obesity treatment startup Ilant Health launches with $3M

Last year

VedaBio launches with $40M+ in initial funding for CRISPR-based molecular detection technology

Last year

Biotech in Israel: Holding on to business as usual amid uncertain times

Last year

Agomab draws $100M for fibrosis pipeline, adding to drumbeat of nine-figure Series C rounds

Last year

Novartis, Bristol Myers back $61M Series A raise for dementia biotech AstronauTx

Last year

BMS-backed liquid biopsy biotech Precede Biosciences debuts to enhance precision medicine approaches

Last year

AI-driven biotech Iambic snags $100M to enter the clinic next year in HER2 field

Last year

The Endpoints Slack interview: Cellino CEO Nabiha Saklayen on cell therapy's future, Elon Musk and time travel

Last year

Health tech funding levels out as startups raise $2.5B in third quarter

Last year

Flagship poaches another pharma R&D leader as GSK's Lepore heads to ProFound

Last year

Stem cell startup Thymmune lands $37M from Biden's ARPA-H for immune-rejuvenating therapies

Last year

Big Pharma-backed Sitryx locks an additional $39M in a Series A raise to advance its immunometabolic pipeline

Last year

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

Last year

For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activation

Last year

LB Pharmaceuticals raising $75M for schizophrenia drug as Karuna looks to change the field

Last year

After Versanis success, Aditum launches Celexor Bio with autoimmune drug from Acelyrin partner Inmagene

Last year

The Endpoints 11: The biotech startups making the biggest bets with the most exciting science in 2023

Last year

A new George Church startup raises $16M. The first-time founders have a ‘crazy vision’ to bring ML to cell therapy

Last year

Tolremo raises $39M Series A to advance drug designed to dismantle early cancer defenses

Last year

RNA editing startup launches with $30M based on Stanford and University of Tübingen research

Last year

With covalent meds abuzz, RA Capital and Novartis lead $56M seed round for new startup

Last year

First page Previous page 24 25 262728 29 30 Next page Last page